Startup profile · funding coverage
Gilgamesh Pharmaceuticals funding, valuation and investors
Neuropsychiatric drug development with a historical Ayuh Ventures investment.
Verified company research · funding, investors and latest developments
Keep track of Gilgamesh Pharmaceuticals
Save this profile to your VCT watchlist for a quick return.
Funding, valuation & investors
Answer-first snapshotLatest funding
Not publicly disclosed
Latest known valuation
Not publicly disclosed
Total disclosed equity funding
Not publicly disclosed
Excludes debt, grants, acquisitions, secondaries, and IPO proceeds.
Current status
private
Stage not recorded
Overview
Gilgamesh Pharmaceuticals develops investigational therapies for psychiatric conditions. Ayuh Ventures names the company in its selected portfolio. In October 2025, AbbVie completed the acquisition of Gilgamesh's bretisilocin asset. That transaction should not be described as acquisition of every Gilgamesh program: the company continues to describe other neuropsychiatric development programs on its website. Ayuh's current ownership and realized proceeds have not been disclosed here.
Why Gilgamesh Pharmaceuticals is interesting
Gilgamesh illustrates a biotech path from molecule development to a strategic pharmaceutical transaction. Distinguishing an asset acquisition from a whole-company acquisition is essential when interpreting the company's history and its investors' outcomes.
Product & use cases
The company describes a pipeline of novel chemical entities and neuropsychiatric programs. Bretisilocin, also known as GM-2505, was the subject of AbbVie's completed acquisition. Other programs and subsequent financing should be evaluated separately from the historical Ayuh relationship.
- Development of investigational neuropsychiatric therapies.
- Clinical research and pharmaceutical development partnerships.
Key facts
- Named on Ayuh Ventures' official website.
- AbbVie completed its bretisilocin asset acquisition on October 17, 2025.
- No realized return or current Ayuh ownership percentage is inferred from the transaction.
Investors in our directory
Funds linked from Gilgamesh Pharmaceuticals's profile — open a fund page for stage focus and related deal articles.
Industries
Market / IPO context
Editorial / static context — not a live quote.
FAQs about Gilgamesh Pharmaceuticals
Practical answers founders, operators, and investors typically search for.
Last updated:
Editorial note: AI tools assisted with research, structure, or drafting. Venture Capital Tracker retains human editorial responsibility for factual accuracy, relevance, and source quality before publication.